Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398272 | 0.88 | ALDH1A1 (0.40) | MEN1KMT2ACTSGCMA1NPC1 | |
| SCHEMBL5409768 | 0.85 | HPGD (0.39) | HPGDNPC1RAB9APKMTSHR | |
| SCHEMBL5408657 | 0.83 | RAB9A (0.42) | MEN1KMT2ARAB9ALPAR1TSHR | |
| SCHEMBL5401055 | 0.83 | ALDH1A1 (0.41) | MEN1KMT2ACTSGCMA1HIF1A | |
| SCHEMBL5409459 | 0.83 | KDM4E (0.39) | MEN1KMT2ACTSGCMA1BCHE | |
| SCHEMBL5405939 | 0.83 | MEN1 (0.37) | MEN1KMT2AHPGDCTSGCMA1 | |
| SCHEMBL5402546 | 0.82 | KMT2A (0.47) | MEN1KMT2AHPGDCTSGCMA1 | |
| SCHEMBL5405706 | 0.81 | POLB (0.40) | MEN1KMT2ACTSGCMA1LPAR1 | |
| SCHEMBL5409603 | 0.81 | TDP1 (0.36) | KMT2ALPAR1 | |
| SCHEMBL5402977 | 0.81 | LPAR1 (0.47) | MEN1KMT2ACTSGCMA1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | MEN1 891/4885KMT2A 2451/4885HPGD 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.